Introduction to ECHO and Biomarker Testing Guidelines Overview
This session provided an overview of the ECHO model, along with providing a data level-set of the current burden of lung cancer in each state, and provide a brief introduction to lung cancer biomarker testing, including the current guidelines and approved FDA biomarker-driven treatments.
Didactic Presenter
DuyKhanh Pham “Mimi” Ceppa, MD, FACS
Aakash Desai, MBBS, MPH
Understanding the Barriers and Pathways to Lung Cancer Biomarker Testing
This session will provide an overview of the biomarker continuum through the lens of the critical medical stakeholders, showcasing the coordinated sequence of events that is required and the common gaps at every stage of the multidisciplinary care continuum.
Didactic Presenter
Millie Das, MD
View Resources
Lung Cancer Biomarker Testing ECHO Year 3 – Session 1 – 1-17-24 – Recording
Lung Cancer Biomarker Testing ECHO Year 3 – Session 1 – 1-17-24 – Slides
Lung Cancer Biomarker Testing ECHO Year 3 – Session 1 – 1-17-24 – Case Presentation
Lung Cancer Biomarker Testing ECHO Year 3 – Session 1 – 1-17-24 – Recap & Resources
Adequate Tissue for Sampling
This session will define the overall role of the multidisciplinary care team, including the coordination by pathologists and medical oncologists to ensure adequate lung cancer tissue is collected for testing. Additionally, it will provide guidance on how to procure adequate tissue samples that allow for accurate characterization of histology, biomarker testing, and the tissue and discuss the approaches of the different proceduralists.
Didactic Presenter
Nichole T. Tanner, MD, MSCR
View Resources
Lung Cancer Biomarker Testing ECHO Year 3 – Session 2 – 2-9-24 – Recording
Lung Cancer Biomarker Testing ECHO Year 3 – Session 2 – 2-9-24 – Slides
Lung Cancer Biomarker Testing ECHO Year 3 – Session 2 – 2-9-24 – Case Presentation
Lung Cancer Biomarker Testing ECHO Year 3 – Session 2 – 2-9-24 – Recap & Resources
Choice of Panel, Interpretation of Results, and Next Steps
This session will provide guidance and recommendations regarding the appropriate biomarker testing modalities (next-generation sequencing (NGS), Fluorescence in situ hybridization (FISH), and blood. Additionally, it will discuss how to interpret the current NGS reports and the appropriate next steps, e.g. recommendations for FDA approved treatments or cancer clinical trials (if no FDA approved treatment exists, etc.).
Didactic Presenter
Ignacio Wistuba, MD
View Resources
Lung Cancer Biomarker Testing ECHO Year 3 – Session 3 – 3-6-24 – Recording
Lung Cancer Biomarker Testing ECHO Year 3 – Session 3 – 3-6-24 – Slides
Lung Cancer Biomarker Testing ECHO Year 3 – Session 3 – 3-6-24 – Case Presentation
Lung Cancer Biomarker Testing ECHO Year 3 – Session 3 – 3-6-24 – Recap & Resources
Improving Turnaround Time
This session will offer strategies to reduce turnaround time and present approaches to help ameliorate the patient’s wait time for the results.
Didactic Presenter
Jason Merker, MD, PhD
Navigating Insurance Challenges
This session will explore the current coverage policies and reimbursement for single gene tests, as compared to multi-gene panel tests by private and public payers in each state and provide solutions to overcome reimbursement barriers.
Series Wrap Up and Next Steps
Our Experts
Bruce Johnson, MD, FASCO
Professor of Medicine, Harvard Medical School
Senior Advisor to the President,
Timothy Mullett, MD, MBA, FACS
Medical Director, Markey Cancer Center Network Development
Millie Das, MD
Chief, Oncology
VA Palo Alto Health Care System
Clinical Associate Professor
Aakash Desai, MBBS, MPH
Assistant Professor Of Medicine
O’Neal Cancer Center
DuyKhanh Pham “Mimi” Ceppa, MD, FACS
Associate Professor of Thoracic Surgery
Jason Merker, MD, PhD
Associate Professor, Department of Pathology and Laboratory Medicine & Genetics
University of North Carolina
Catherine R. Sears, MD
Associate Professor of Medicine, Division of Pulmonary, Critical Care, Sleep and Occupational Medicine
Indiana University School of Medicine
Gerard Silvestri, MD, MS
Hillenbrand Professor of Thoracic Oncology
Heather Wakelee, MD
Professor of Medicine and Chief of the Division of Oncology, Stanford University School of Medicine
Deputy Director,
Ignacio Wistuba, MD
Professor and Chair, Department of Translational Pathology
Financial Support Provided By
Need Assistance
Complete the fields below to learn more about how the American Cancer Society uses the ECHO Model to fight cancer on all fronts, inquire about an upcoming ECHO, or to learn how you can join us in our mission to save lives, celebrate lives, and lead the fight for a world without cancer.
Contact Us
